"This is a historic moment for 4DMT as we become a Phase 3 company following our initiation of the 4FRONT-1 clinical trial,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT ...

Die nächste Aktie, die ich kaufe, steht für mich fest: Es wird sich um die Aktie von Ulta Beauty (WKN: A0M240) handeln. Das wiederum liegt an mehreren Faktoren: Einem Geschäft, das zumindest ...

A mid-stage trial of 4D Molecular Therapeutics gene therapy for eye disease age-related macular degeneration (AMD) 4D-150 has shown promising signs of efficacy, plus a reduced need for injections ...

We are currently undergoing maintenance on some services, which may temporarily affect access to subscription accounts and the E-edition. We apologize for any inconvenience and appreciate your ...

4D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) from the retina with a single, safe, intravitreal injection.

Wet AMD is a highly prevalent disease, with more than 4 million individuals expected to be affected in the next five years in certain major markets, including the U.S., the EU and Japan. The disease ...

4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level 3E10 vg/eye demonstrated strong signals of clinical activity with sustained gain of BCVA ...

This is a great opportunity to join our dynamic team of Toxicologists at a great company! Please review the link below and consider applying for this position! https://smrtr.io/pw4Dw ...